IGFBP-3 Nuclear Localization Predicts Human Prostate Cancer Recurrence

Hormones and Cancer

Volumn 4, Issue 1, 2013, Pages 12-23

  Seligson, David B ^a   Yu, Hong ^a   Tze, Sheila ^a   Said, Jonathan ^a   Pantuck, Allan J ^a   Cohen, Pinchas ^a,b   Lee, Kuk Wha ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE MICROARRAY;

EID: 84872349394     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-012-0124-8     Document Type: Article

References (38)

1. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schroder F (2009) Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 55(6): 1321-1330.
2. Catalona WJ, Smith DS (1998) Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 160(6 Pt 2): 2428-2434.
3. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279(5350): 563-566.
4. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E (2002) Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94(14): 1099-1106.
5. Cohen P (2006) Insulin-like growth factor binding protein-3: insulin-like growth factor independence comes of age. Endocrinology 147(5): 2109-2111.
6. D'Amico AV, Renshaw AA, Arsenault L, Schultz D, Richie JP (1999) Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy. Int J Radiat Oncol Biol Phys 45(4): 841-846.
7. Dowsett M, Dunbier AK (2008) Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 14(24): 8019-8026.
8. Epstein JI (2010) An update of the Gleason grading system. J Urol 183(2): 433-440.
9. Figueroa JA, De Raad S, Tadlock L, Speights VO, Rinehart JJ (1998) Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J Urol 159(4): 1379-1383.
10. Fine SW, Epstein JI (2008) A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. J Urol 179(4): 1335-1338, discussion 1338-1339.
11. Fleming ID, Cooper JS, Hensen DE, Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbro JW (eds) (1997) American Joint Commitee on Cancer: AJCC Cancer Staging Manual, 5th edn. Lippincott-Raven, Philadelphia, pp 309-312.
12. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA: J Am Med Assoc 294(4): 433-439. doi: 10. 1001/jama. 294. 4. 433.
13. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA et al (2003) Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 55(1): 71-80.
14. Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111(1): 58-64.
15. Hampel OZ, Kattan MW, Yang G, Haidacher SJ, Saleh GY, Thompson TC, Wheeler TM, Marcelli M (1998) Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. J Urol 159(6): 2220-2225.
16. Han J, Jogie-Brahim S, Harada A, Oh Y (2011) Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-kappaB signaling. Cancer Lett 307(2): 200-210.
17. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169(2): 517-523.
18. Harrell FE (2001) Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. Springer Publishing, New York.
19. Humphrey PA, Frazier HA, Vollmer RT, Paulson DF (1993) Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels. Cancer 71(5): 1821-1827.
20. Ingermann AR, Yang YF, Han J, Mikami A, Garza AE, Mohanraj L, Fan L et al (2010) Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J Biol Chem 285(39): 30233-30246.
21. Jamali M, Chetty R (2008) Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol 19(4): 282-288.
22. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5): 277-300.
23. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7): 844-847.
24. Lee KW, Liu B, Ma L, Li H, Bang P, Koeffler HP, Cohen P (2004) Cellular internalization of insulin-like growth factor binding protein-3: distinct endocytic pathways facilitate re-uptake and nuclear localization. J Biol Chem 279(1): 469-476.
25. Lee KW, Ma L, Yan X, Liu B, Zhang XK, Cohen P (2005) Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77. J Biol Chem 280(17): 16942-16948.
26. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P (2007) Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 26(12): 1811-1819.
27. Malhotra S, Lapointe J, Salari K, Higgins JP, Ferrari M, Montgomery K, van de Rijn M, Brooks JD, Pollack JR (2011) A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer. PLoS One 6(5): e20293.
28. Massoner P, Colleselli D, Matscheski A, Pircher H, Geley S, Jansen Durr P, Klocker H (2009) Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility. Endocr-relat Cancer 16(3): 795-808.
29. Mehta HH, Gao Q, Galet C, Paharkova V, Wan J, Said J, Sohn JJ et al (2011) IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res 71(15): 5154-5163.
30. Miyata Y, Sakai H, Kanda S, Igawa T, Hayashi T, Kanetake H (2004) Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence. Urology 63(6): 1184-1190.
31. Paharkova-Vatchkova V, Lee KW (2010) Nuclear export and mitochondrial and endoplasmic reticulum localization of IGF-binding protein 3 regulate its apoptotic properties. Endocr-relat Cancer 17(2): 293-302.
32. Pernicova Z, Slabakova E, Kharaishvili G, Bouchal J, Kral M, Kunicka Z, Machala M, Kozubik A, Souccek K (2011) Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2. Neoplasia 13(6): 526-536.
33. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA: J Am Med Assoc 281(17): 1591-1597.
34. Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM, Slawin KM (2002) Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 20(3): 833-841.
35. Silha JV, Sheppard PC, Mishra S, Gui Y, Schwartz J, Dodd JG, Murphy LJ (2006) Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 147(5): 2112-2121.
36. Terracciano D, Bruzzese D, Ferro M, Mazzarella C, Di Lorenzo G, Altieri V, Mariano A, Macchia V, Di Carlo A (2011) Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading. The Prostate 2012, 72: 100-7.
37. Yamada PM, Lee KW (2009) Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am J Physiol Cell Physiol 296(5): C954-C976.
38. Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla A (2000) Tumors of the prostate gland, seminal vesicle, male urethra, and penis. In Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology, pp 210.